The company was founded in 1996 and successfully listed on the Shenzhen Stock Exchange in June 2010. It immediately launched a 10 billion industrial investment plan and began implementing the “three-engine drive, innovative growth” development strategy. The company is mainly engaged in R&D, production and sales of 24 types of pharmaceuticals, including large-volume injections (infusions), small-volume injections (including dispensed powder needles and freeze-dried powder needles), tablets, capsules, granules, oral solutions, peritoneal dialysis solutions, etc., as well as products such as antibiotic intermediates, APIs, pharmaceutical packaging materials, etc. The company's main products are infusion products, pharmaceutical products in other dosage forms, raw materials, pharmaceutical excipients, antibiotic intermediates, and medical devices. Corporate honors: National Technological Innovation Demonstration Enterprise, Industrial Brand Cultivation Demonstration Enterprise, National Science and Technology Progress Award, etc.